Loading…
Loading…
Popular, Inc. (BPOP) Q2 2026 Earnings Call Transcript
Popular NASDAQ: BPOP reported a stronger second quarter, with management citing higher net interest income, solid fee generation, balance sheet growth and stable underlying credit trends, while also announcing a leadership transition and expanded capital returns.
Popular (BPOP) came out with quarterly earnings of $4.35 per share, beating the Zacks Consensus Estimate of $3.69 per share. This compares to earnings of $3.09 per share a year ago.
SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Popular, Inc. (the “Corporation”) (NASDAQ: BPOP) announced today the following capital actions: an increase in the Corporation's quarterly common stock dividend from $0.75 to $0.90 per share, commencing with the dividend payable in the fourth quarter of 2026, subject to the approval of the Corporation's Board of Directors; and a new common stock repurchase authorization of up to $1 billion. The Corporation's planned common stock repurchases may be execute.
SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Popular, Inc. (the “Corporation,” “Popular,” “we,” “us,” “our”) (NASDAQ: BPOP) FINANCIAL HIGHLIGHTS ($ in millions, except per share information) Quarters ended 30-Jun-26 31-Mar-26 Δ vs 31-Mar-26 30-Jun-25 Δ vs 30-Jun-25 EARNINGS Net Income $ 278 $ 246 $ 32 $ 210 $ 68 PER SHARE DATA Basic EPS $ 4.35 $ 3.78 $ 0.57 $ 3.09 $ 1.26 Diluted EPS $ 4.35 $ 3.78 $ 0.57 $ 3.09 $ 1.26 Tangible Book Value / Share (no.
SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Popular, Inc. (“Popular” or the “Company”) (NASDAQ: BPOP) announced today that Javier D. Ferrer, the Company's President and Chief Executive Officer, will retire effective August 31, 2026. Jorge J. García, the Company's Executive Vice President and Chief Financial Officer, will succeed Ferrer as President and Chief Executive Officer and a member of the Board. In connection with this appointment, Lidio V. Soriano, Executive Vice President and Chief Risk Of.
Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs.
As space becomes scarce, the company is experimenting with new store formats.
SEC filings for BPOP aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.